Toro Labs Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors simultaneously, representing a next-generation approach to metabolic research.
Key Details
– 30mg per vial
– Lyophilised (freeze dried) powder
– Requires reconstitution with bacteriostatic water
– Batch tested via HPLC analysis
– Toro Labs authenticated product
Research Benefits
– Triple receptor agonist — GLP-1, GIP, and glucagon
– Demonstrates superior fat reduction in clinical research versus dual agonists
– Promotes significant reductions in body weight and visceral adiposity
– Supports improvements in cardiometabolic markers
– Studied for non-alcoholic fatty liver disease applications
Suggested Research Protocol
– Starting dose: 1mg per week
– Titrate by 2mg every 4 weeks
– Maintenance dose: 8mg to 12mg per week
– Administered via subcutaneous injection
– Store reconstituted vial refrigerated at 2 to 8C
Quality Assurance: Every vial is batch coded and lab verified. Full HPLC purity reports available on request. Manufactured under strict ISO conditions by Toro Laboratories.
Reviews
There are no reviews yet.